Adma Biologics (ADMA) Times Interest Earned (2011 - 2026)
Adma Biologics' (ADMA) quarterly Times Interest Earned came in at -$103.38 in Q4 2025, down 2492.2% YoY from $4.32 in Q4 2024, and down 1054.92% on a QoQ basis from $10.83 in Q3 2025.
Adma Biologics (ADMA) Times Interest Earned (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Times Interest Earned data on file, last reported at -$103.38 in Q4 2025.
- Quarterly Times Interest Earned fell 2492.2% year-over-year to -$103.38 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.32 (up 76.53% YoY) and the FY2025 annual result came in at $4.86, up 138.25% from the prior year.
- Times Interest Earned eased to -$103.38 in Q4 2025, from $10.83 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $11.33 in Q3 2024 to a low of -$103.38 in Q4 2025.
- A 5-year average of -$5.71 and a median of -$0.1 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned jumped 13899.75% — and 2025, when it sank 2492.2%.
- Tracing ADMA's Times Interest Earned over 5 years: stood at -$43.97 in 2021, then jumped by 97.6% to -$1.06 in 2022, then soared by 316.84% to $2.29 in 2023, then jumped by 88.7% to $4.32 in 2024, then slumped by 2492.2% to -$103.38 in 2025.
- The last three Times Interest Earned figures came in at -$103.38 (Q4 2025), $10.83 (Q3 2025), and $2.78 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 5.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.32 |
| Dec 31, 2025 | -103.38 |
| Sep 30, 2025 | 10.83 |
| Jun 30, 2025 | 2.78 |
| Mar 31, 2025 | 7.32 |
| Dec 31, 2024 | 4.32 |
| Sep 30, 2024 | 11.33 |
| Jun 30, 2024 | 10.36 |
| Mar 31, 2024 | 5.79 |
| Dec 31, 2023 | 2.29 |
| Sep 30, 2023 | 1.36 |
| Jun 30, 2023 | -0.08 |
| Mar 31, 2023 | -0.13 |
| Dec 31, 2022 | -1.06 |
| Sep 30, 2022 | -1.67 |
| Jun 30, 2022 | -2.01 |
| Mar 31, 2022 | -4.37 |
| Dec 31, 2021 | -43.97 |
| Sep 30, 2021 | -4.38 |
| Jun 30, 2021 | -4.80 |